Pfizer Viagra Patent Ruled Valid by Judge in Loss for Teva
This article is for subscribers only.
A Pfizer Inc. patent for the impotence pill Viagra is valid, a U.S. judge ruled, blocking Teva Pharmaceutical Industries Ltd. from marketing a generic version until 2019.
The decision, protecting Pfizer’s $1 billion a year in U.S. Viagra sales for most of the next decade, was handed down Aug. 12 after a two-week non-jury trial that began June 15, according to court papers.